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Abstract: Tigecycline is a member of the glycylcycline class of antimicrobials, which is 
structurally similar to the tetracycline class. It demonstrates potent in vitro activity against 
causative pathogens that are most frequently isolated in patients with community-acquired 
bacterial pneumonia (CABP), including (but not limited to) Streptococcus pneumoniae (both 
penicillin-sensitive and -resistant strains), Haemophilus influenzae and Moraxella catarrhalis 
(including β-lactamase-producing strains), Klebsiella pneumoniae, and ‘atypical organisms’ 
(namely   Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). 
Comparative randomized clinical trials to date performed in hospitalized patients receiv-
ing   tigecycline 100 mg intravenous (IV) × 1 and then 50 mg IV twice daily thereafter have 
  demonstrated efficacy and safety comparable to the comparator agent. Major adverse effects 
were primarily gastrointestinal in nature. Tigecycline represents a parenteral monotherapy 
option in   hospitalized patients with CABP (especially in patients unable to receive respira-
tory fluoroquinolones). However, alternate and/or additional therapies should be considered 
in patients with more severe forms of CABP in light of recent data of increased mortality in 
patients receiving tigecycline for other types of severe infection.
Keywords: tigecycline, glycylcycline, community-acquired pneumonia
Introduction
Community-acquired bacterial pneumonia (CABP) is a leading cause of   morbidity 
and mortality in the United States.1–3 An estimated 5–6 million cases per year result 
in   hospitalization rates of ∼20% and (among hospitalized patients) a mortality rate 
of 12%.1–3 Organisms most commonly isolated in patients with CABP include 
Streptococcus pneumoniae (S. pneumoniae) (the most common),   Haemophilus 
influenzae, Moraxella catarrhalis (M. catarrhalis), Klebsiella pneumoniae 
(K.   pneumoniae), and ‘atypical organisms’ (namely Chlamydophila pneumoniae 
(C.   pneumoniae), Mycoplasma pneumoniae (M. pneumoniae), and Legionella pneu-
mophila (L. pneumophila)).4–6 Other Gram-negative bacilli and Staphylococcus aureus 
infrequently cause CABP, except in patients with severe disease and/or select underly-
ing comorbidities.4,6 Antimicrobial resistance among these organisms continues to be a 
growing concern. For example, rates of multidrug-resistant S. pneumoniae have been 
reported to be .30% worldwide, and the rates of β-lactamase-producing H. influenzae 
ranges from 12% to 27%.7–9
Current published guidelines for the empiric treatment of CABP in hospi-
talized patients not admitted to the intensive care unit (ICU) generally include Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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either   monotherapy with a respiratory fluoroquinolone 
  (gemifloxacin, moxifloxacin, or   levofloxacin) or a combina-
tion of a β-lactam (such as   ceftriaxone or cefotaxime) in 
combination with a macrolide.4–6 Alternative monotherapy 
options in such patients unable to receive a respiratory 
  fluoroquinolone are lacking.
Tigecycline is a member of the glycylcycline class of 
antimicrobials, which is structurally similar to the tetracycline 
class.10 It possesses favorable activity in vitro against a broad 
spectrum of aerobic Gram-positive, Gram-negative, anaero-
bic, and ‘atypical’ microorganisms, including those most 
frequently associated with CABP.10 Previously published 
controlled clinical trials have established its effectiveness 
in the treatment of both complicated skin and skin structure 
infections (cSSSIs) and complicated intra-abdominal infec-
tions (cIAIs).11–14 More recently, tigecycline has been studied 
for the treatment of CABP.15–17 Our objective is to provide an 
overview of tigecycline’s activity, clinical efficacy, safety, 
and potential role in the treatment of CABP.
Overview of tigecycline
Pharmacology
Tigecycline acts by binding to the bacterial ribosomal   subunit 
30 S, resulting in inhibition of protein synthesis.11 The   resulting 
activity is time-dependent bacteriostatic against most organ-
isms, although bactericidal activity has been observed with 
S. pneumoniae and L. pneumophilia isolates.11 The in vitro 
post-antibiotic effect of tigecycline against Staphylococcus 
aureus, S. pneumoniae, and Gram-negative organisms has 
ranged from .3 to 4.1, 8.9, and 2 to 5 h, respectively.11
Tigecycline’s in vitro activity appears unaffected by 
β-lactamase production, alterations in the target site, or 
target enzymes.11 It also appears to be unaffected by most 
resistance mechanisms affecting the tetracyclines (such as 
ribosomal protection and select efflux pumps).18–25 However, 
the most common mechanisms of resistance to tigecycline 
does appear to involve efflux pumps.11 One particular 
type of efflux pump (known as the ‘resistance nodulation 
  division’) has been noted in isolates of Pseudomonas 
aeruginosa,   Acinetobacter baumannii (A. baumannii), 
Serratia   marcescens, and   Enterobacter cloacae.26–29 Such 
efflux pumps, especially those found with A. baumannii, 
are associated with multidrug resistance.29 Efflux pumps to 
tigecycline have also been observed in Burkholderia spp.30 
In K. pneumoniae, resistance to tigecycline expression of 
the mutant ramR gene resulted in alterations of the bacterial 
genome such as deletions,   insertions, and point mutations 
that led to reduced susceptibility to tigecycline.31
Microbiology
Tigecycline is a broad-spectrum antimicrobial agent that 
has in vitro activity against a variety of facultative aerobic 
  Gram-positive, Gram-negative, and anaerobic bacteria 
(Table 1). According to the Clinical Laboratory Standards 
Institute, the minimum inhibitory concentration (MIC) 
considered susceptible to tigecycline is #0.5 mg/L for 
 Staphylococcus aureus (including methicillin-resistant 
organisms), #0.25 mg/L for non–Streptotoccus pneumoniae, 
Streptococcus spp, and Enterococcus faecalis isolates.32,33 
For S. pneumoniae, the susceptibility MIC breakpoint 
is #0.06 mg/L.32,33 The MIC considered susceptible for 
  Enterobacteraceae and H. influenzae is #2 and #0.25 mg/L, 
respectively.32,33 Anaerobes are deemed susceptible to 
  tigecycline if the MIC is #4 mg/L.33,34
Tigecycline demonstrates potent activity in vitro data 
against most relevant Gram-positive organisms. Isolates of 
Staphylococcus aureus (n = 8765) displayed 99.4% suscep-
tibility, with MIC90 and ranges of 0.5 and #0.016–1 mg/L, 
respectively.35 In vitro susceptibilities of   coagulase-negative 
Staphylococcus (n = 3570), Enterococcus spp (n = 3258), 
β-hemolytic Streptotocci (n = 769), and viridans group 
  Streptococci (n = 378) were 97.5%, 92.7%, 99.7%, and 
98.1%, respectively.35 Of particular relevance to CABP, tige-
cycline displays potent in vitro activity against S. pneumoniae. 
A total of 92.7% of 605 isolates were   susceptibile to tigecy-
cline, with MIC90 and ranges of #0.12 and #0.12–1 mg/L, 
  respectively.35 Tigecycline’s   activity also includes penicillin-
intermediate and penicillin-resistant S. pneumoniae 
organisms, with 90.2% (n = 1077) and 91.2% (n = 555) 
susceptibility, respectively, for North American isolates.36 
In addition, a tigecycline MIC of 0.12 mg/L was reported 
against a   fluoroquinolone-resistant S.   pneumoniae.37 Although 
not common,   community-associated   methicillin-resistant 
  Staphylococcus aureus (CA-MRSA) may cause CABP 
(most notably in patients with post-influenza bacterial 
pneumonia).38–40 In such cases, mortality rates approach 30%.39 
CA-MRSA is often characterized by the presence of 
Panton–Valentine leukocidin (PVL) cytotoxin, although 
its contribution to organism virulence is   controversial.38 
Tigecycline exhibits favorable in vitro activity against 
  CA-MRSA isolates (98.2% susceptibility rate) (n = 1989).41 
Tigecycline has also been reported to reduce the expression 
of the PVL gene, resulting in a 10-fold reduction in toxin 
production.41,42
Tigecycline also exhibits potent in vitro activity against 
many Gram-negative organisms, with notable excep-
tions including Proteus and Pseudomonas spp.35 In one Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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  intercontinental study involving over 26,000 isolates, 
many Gram-negative organisms displayed over 95% sus-
ceptibility to tigecycline.35 This included Escherichia coli 
(E. coli) (n = 3217; 0.25 and 0.03–4 mg/L), Enterobacter 
spp (n = 801; 2 and 0.06–8 mg/L), and Klebsiella spp 
(n = 1503; 1 and 0.06–8 mg/L) for isolate numbers, MIC90, 
and range, respectively.35 Other Gram-negative organisms 
that are often susceptible to tigecycline include Serratia 
spp (n = 294, 94.6% susceptible), Stenotrophomonas 
maltophilia (n = 203, 93.1% susceptible), and Acineto-
bacter spp (n = 326, 94.5% susceptible).35 Of relevance to 
Gram-negative pathogens causing CABP, tigecycline dis-
plays potent in vitro activity against H. influenzae (includ-
ing resistant isolates such as β-lactamase   producers) and 
M. catarrhalis.36,43 In one study of respiratory tract organ-
isms, M. catarrhalis isolates (n = 2314) demonstrated 
tigecycline MIC90 and ranges of 0.5 and #0.06–4 mg/L.43 
In another study, North   American H. influenzae isolates 
had MIC90 and ranges of 0.5 and #0.008–2 mg/L for 
β-lactamase-producing H. influenzae (n = 904) and 0.5 
and 0.015–2 mg/L for β-lactamase negative, ampicillin-
resistant H. influenzae isolates (n = 34), respectively.36 
While generally not of concern as etiologic agents in 
CABP, tigecycline displays favorable in vitro activity 
against extended-spectrum β-lactamase (ESBL)-produc-
ing E. coli and K. pneumoniae.44,45 For example, 90.7% 
of 150 isolates of ESBL-producing K. pneumoniae were 
considered susceptible to tigecycline.46 A regional study 
examined ESBL-producing E. coli isolates and reported 
susceptibilities of 94.7% (n = 19), 89.2% (n = 65), and 
95.5% (n = 22) in the East North Central, Middle Atlantic, 
and South Atlantic regions of the USA, respectively.47
The in vitro activity of tigecycline against anaerobes has 
been studied, and tigecycline displayed excellent potency 
against Clostridium perfringens,   Peptostreptococcus micros, 
Bacteroides fragilis, Bacteroides   thetaiotaomicron, and Bacte-
roides uniformis.48 While not frequent causes of CABP, anaero-
bic pathogens may be of concern in cases of   aspiration.49 
Organisms such as C. pneumoniae, M.   pneumoniae, 
and L. pneumophilia have also been reported as   etiologies 
to CABP.50–53 The MIC90 and ranges for tigecycline were 
0.125 and 0.125–0.25 mg/L for C. pneumoniae (n = 10), 8 
and 0.5–8 mg/L for Legionella spp (n = 100), and 0.25 and 
0.06–0.25 mg/L for M. pneumoniae.50–53
Pharmacokinetics/pharmacodynamics
Tigecycline exhibits linear kinetics, with a two-compartment 
model following intravenous (IV) administration.54,55 Data 
from healthy volunteers (n = 103) receiving tigecycline 100 mg 
as a loading dose followed by 50 mg every 12 h demonstrated 
a maximum plasma concentration (Cmax) of 0.63 µg/mL after a 
60-min infusion and a minimum plasma concentration (Cmin) of 
0.13 µg/mL.11,54 The area under the plasma concentration–time 
curve from 0 to 24 h (AUC0–24) was 4.7 µg ⋅ h/mL.54 Similar 
pharmacokinetic parameters have been noted in phase III clini-
cal studies of patients with cSSSIs and cIAIs. 56,57
Tigecycline is highly protein bound (71%–89%) at plasma 
drug concentrations of 0.1–1.0 µg/mL and exhibits a large 
volume of distribution (Vd) at steady state of 7–9 L/kg in 
healthy volunteers.11,54 Animal and human studies have dem-
onstrated that tigecycline can distribute into various tissues 
and body fluids (such as the lungs, skin,   peritoneal fluid, 
gallbladder, colon, heart, liver, meninges, and bone).11,58–64 
In a study of adult patients (n = 104) undergoing medical 
Table 1 In vitro activity of tigecycline against common CABP respiratory pathogensa
Bacteria No. of isolates MIC90 MIC range (in mg/L) References
Typical pathogens
  S. pneumoniae 6456 0.06 #0.008–1 95
  S. pneumoniae, penicillin-intermediate susceptible 1077b 0.06 NR 36
  S. pneumoniae, penicillin resistant 891 0.06 #0.008–0.25 95
  H. influenzae 6070 0.5 #0.008–2 95
  H. influenzae, β-lactamase positive 1346 0.5 #0.008–2 95
  Klebsiella pneumoniae 10,644 2 #0.008–16 95
  Moraxella catarrhalis 2314 0.5 #0.06–4 43
Atypical pathogens
  Chlamydia pneumoniae 10 0.125 0.125–0.25 51
  Legionella sppc 100 8 0.5–8 52,53
  Mycoplasma pneumoniae 30 0.25 0.06–0.25 50
Notes: aAccording to the Clinical Laboratory Standards Institute (CLSI), the MICs considered susceptible are as follows: S. pneumoniae # 0.06 mg/L, H. influenzae #0.25 mg/L, 
and enterobacteraciae # 2 mg/L; bData from North American isolates; cIsolates (n = 50) of Legionella pneumophilia are represented.
Abbreviations: CABP, community-acquired bacterial pneumonia; MIC, minimum inhibitory concentration; NR, not reported; S. pneumoniae, Streptococcus pneumoniae; 
H. influenzae, Haemophilus influenzae.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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or   surgical procedures, tigecycline concentrations were 
  evaluated 4 h after the administration of 100 mg over 
30 min.63 The highest concentration of tigecycline was found 
in the bile. The mean ratio of tigecycline in the tissue to 
serum (expressed as AUC0–24) was 537 in the bile, 23 in the 
  gallbladder, 2.6 in the colon, 2.0 in the lung, 0.41 in bone, 
0.31 in synovial fluid, and 0.11 in cerebrospinal fluid.
Lung penetration of tigecycline has been evaluated 
in healthy adults (n = 30) after receiving a loading dose 
of 100 mg of tigecycline followed by six doses of 50 mg 
every 12 h.60 The AUC0–12 was 1.73 µg ⋅ h/mL in the serum, 
134 µg ⋅ h/mL in the alveolar cells (ACs), and 2.28 µg ⋅ h/mL 
in the epithelial lining fluid (ELF). The corresponding Cmax 
was 0.72, 15.2, and 0.37 µg/mL, respectively. In adult 
critically ill mechanically ventilated patients (n = 3), mean 
tigecycline concentrations 4 h following the infusion were 
0.36 ± 0.20, 0.02 ± 0.01, and 8.96 ± 0.15 mg/L in the plasma, 
ELF, and ACs, respectively, after receipt of 100 mg followed 
by 50 mg every 12 h.65 The ratios of ELF and AC concen-
trations relative to plasma concentrations were 0.06 ± 0.02 
and 34.3 ± 7.8, respectively. Although plasma, ELF, and 
AC concentrations are comparable to healthy volunteers, 
the penetration of tigecycline into the extracellular lung 
compartment of these critically ill patients with underlying 
pulmonary pathology (as noted by the ELF to plasma ratio) 
was low.60,66 Although ELF is an intrapulmonary site, con-
centrations within this fluid are believed to be important in 
reflecting potency against extracellular organisms (such as 
S. pneumoniae and K. pneumonia).65,66
Tigecycline is minimally metabolized to nonactive 
metabolites of glucuronide, its epimer M1 and M2, and 
N-acetyl-9-aminominocycline (M6).11,67,68 The primary 
route of elimination of tigecycline is as unchanged drug and 
metabolites through the feces (59%) and biliary tract.67 Renal 
excretion (33%) and glucuronidation are secondary routes of 
elimination. Tigecycline has a terminal half-life of 37–67 h 
and a total systemic clearance of 0.2–0.3 L/h/kg.54
The pharmacokinetic profile of tigecycline has been 
evaluated in several different special patient populations. 
No differences have been noted based on age (18 to .75), 
gender, or race.69,70 Patients with renal insufficiency 
  (creatinine clearance # 30 mL/min) and dependent on 
hemodialysis also did not demonstrate alterations in their 
pharmacokinetic   profiles.71 Tigecycline is not significantly 
removed with   hemodialysis.71 Patients with severe hepatic 
impairment (Child–Pugh class C) demonstrated a 43% 
increase  in  half-life  and  a  55%  decrease  in 
  tigecycline clearance.72 It is   recommended that the 
maintenance dose of   tigecycline should be reduced to 25 mg 
every 12 h in these individuals.11,72,73 In contrast, no adjust-
ment in doses are necessary for patients with mild to moder-
ate (Child–Pugh class A or Child–Pugh class B) hepatic 
impairment.11,72
Based on animal and the clinical data, the AUC to MIC 
ratio (AUC/MIC) is most likely to be the best predictor of 
efficacy with tigecycline.37,69,74 Studies in cSSSIs and cIAIs 
have suggested that the AUC0–24/MIC of $17.9 and $6.96, 
respectively, were predictive of favorable clinical response 
and microbiological eradication.74,75 In two phase III CABP 
studies (n = 68), patients receiving a loading dose of 100 mg 
followed by 50 mg every 12 h had a median AUC0–24/MIC 
of 55.5 (5.2–179.5) with the MICs ranging from 0.03 to 
1.0 mg/L for mono- and poly-microbial S. pneumoniae 
infections.76 Due to the low incidence of clinical and 
microbiological failures, the authors felt that a clear phar-
macokinetics/pharmacodynamics relationship could not 
be established. However, a Classification and Regression 
Tree (CART)-derived AUC/MIC breakpoint of 64 was pre-
dictive of time to fever resolution, since the median time 
to fever resolution for AUC/MIC of $64 and ,64 were 
12 and 24 h, respectively (P = 0.05). In contrast, evalu-
ation of a phase III hospital-acquired pneumonia (HAP) 
study (n = 61) in which patients received standard doses 
of tigecycline, a CART-derived AUC/MIC breakpoint of 
5.75 was significantly associated with clinical success in 
patients (P # 0.02).76 Only 43.2% (7/16) patients with an 
AUC/MIC of ,5.75 achieved clinical success, while 80% 
(36/45) of patients with an AUC/MIC of $5.75 achieved 
clinical success (P = 0.011).
In regards to the treatment of bacteremia, low Cmax con-
centrations obtained after standard dosing of tigecycline are 
concerning, since it approaches the MICs of organisms most 
commonly encountered.77 Furthermore, tigecycline concen-
trations rapidly decline once the Cmax is reached. Animal 
models in neutropenic mice have demonstrated that unbound 
serum concentrations of tigecycline need to be above the 
MIC of the organism for at least 50% of the dosing interval 
in order to achieve maximum effectiveness.63,69,78,79 Therefore, 
organisms would need to have a relatively low MIC to tige-
cycline in order to achieve this pharmacodynamic target in 
bacteremia.60,80 To address this issue, case reports with higher 
dosing schemes of tigecycline (200–400 mg as the loading 
dose followed by 100–200 mg every 24 h) have reported suc-
cess in the treatment of multidrug-resistant K. pneumoniae 
and A. baumannii with higher dosing schemes in order to 
maximize the AUC/MIC.80–82Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Effectiveness of tigecycline  
in the treatment of CABP
Results of two noninferiority, randomized, double-blind, 
multinational, phase III studies have been published, which 
compared the safety and efficacy of tigecycline in compari-
son with levofloxacin.15–17 Febrile, hospitalized adults with 
CABP (confirmed by chest radiograph and at least two of 
the following: symptoms consistent with a bacterial respira-
tory infection, leukocytosis, or hypoxemia) who required 
IV antibiotics were included. Those who failed outpatient 
fluoroquinolones previously, were recently hospitalized, 
resided in a long-term care facility (within 14 days), required 
ICU admission, or had known or suspected infections   
(P . aeruginosa, Legionella pneumonia, or active tuberculosis) 
were excluded. Patients were randomized to receive either tige-
cycline (100 mg IV × 1, then 50 mg IV twice daily thereafter) 
or levofloxacin (500 mg IV daily (one of the trials also had 
the option for 500 mg IV twice daily at the discretion of the 
investigator)). In one of the two trials, patients in either group 
could be switched to oral levofloxacin at the discretion of the 
investigator after 3 days of IV antibiotics. The total duration of 
antimicrobial treatment was 7–14 days in both of these studies. 
The primary end points were clinical response at the test of cure 
(TOC) in both the clinical modified intent-to-treat (c-mITT) and 
the clinically evaluable (CE) populations. In these studies, ‘cure’ 
required the improvement or resolution of clinical signs and 
symptoms attributable to CABP, improvement or no change on 
chest radiograph, and no additional antimicrobials.15–17
Of the 859 patients included in the intent-to-treat (ITT) 
population, 797 and 574 were included in the c-mITT and 
CE populations, respectively. For the tigecycline group, the 
mean age was 52.6 years (±18) with 57.3% male patients; 
the levofloxacin group’s mean age was 51.9 years (±18.7) 
with 62.8% male patients. Fine pneumonia severity index 
scores and confusion, urea nitrogen, respiratory rate, blood 
pressure (CURB-65) criteria were similar among the groups, 
with 80% of the population having scores of I–III for Fine 
and 92% having scores of 0–2 for CURB-65. Concomitant 
diseases (including chronic obstructive pulmonary disease, 
diabetes, liver and renal disease, heart failure and cerebro-
vascular diseases, as well as cancer) were also comparable 
among the two treatment groups. In one of the studies, 
90% and 88% of the tigecycline and levofloxacin groups 
were switched to oral antibiotics after a median of 3.9 and 
3.3 days, respectively.15–17 In the first of the trials, a clinical 
cure rate for the CE and c-mITT populations were 90.6% 
versus 87.2% (absolute difference 3.4% (95% confidence 
interval (95% CI): −4.4% to 11.2%)) and 78.0% versus 
77.8% (absolute difference 0.2% (95% CI: 8.5%–8.9%)) 
for tigecycline and levofloxacin treatments, respectively. 
Similar observations were made in the second trial. Suc-
cess rates in the CE and c-mITT populations were 88.9% 
versus 85.3% (absolute difference 3.6% (95% CI: −4.5% to 
11.8%)) and 83.7% versus 81.5% (absolute difference 2.0% 
(95% CI: −5.5% to 9.6%)) in tigecycline and levofloxacin 
groups, respectively. No differences were noted in clinical 
cure rates among respiratory pathogens, including both typi-
cal and atypical organisms. To be considered noninferior, 
the lower limit of the 95% CI could not exceed −15% for 
the absolute difference. Thus, tigecycline was considered 
noninferior to levofloxacin in both studies.15,16
The safety and efficacy of tigecycline has also been com-
pared to other therapies (such as imipenem–cilastatin) in other 
patient populations with pneumonia, most notably HAP (includ-
ing ventilator-associated pneumonia (VAP) patients).83 In this 
phase III, multicenter, multinational, double-blind   randomized 
trial, tigecycline failed to meet the prespecified noninferiority 
criteria (the lower limit of the 95% CI could not exceed −15% 
for the absolute difference) for the coprimary endpoints of 
clinical response rates at the TOC in the CE (67.9% vs 78.2%, 
absolute difference −10.4% (95% CI: −17.8% to −3%)) 
and c-mITT (62.7% vs 67.6%, absolute difference −4.8% 
(95% CI: −11.0% to 1.3%)) in the tigecycline and imipenem 
groups, respectively. In the VAP subgroup, there were lower 
cure rates (47.9% vs 70.1%), and higher rates of mortality 
(19.1% vs 12.3%) were seen in tigecycline patients relative to 
those receiving imipenem–cilastatin. (See further discussion 
of mortality in the safety and tolerability section.) Patients 
with VAP and bacteremia at baseline had significantly greater 
mortality with 50% (9/18) in the tigecycline population versus 
7.7% (1/13) in the comparator group.83 Until further studies are 
performed, tigecycline should not be recommended for these 
types of patients. As of May 2010, this was an added compo-
nent of the ‘Warnings and Precaution’ section of the Tygacil® 
package insert.11
Case reports of tigecyclines effectiveness in the treat-
ment of pneumonia by various organisms including 
Mycobacterium chelonae,84 multidrug-resistant Stenotro-
phomonas maltophilia,85 and carbapenemase-producing 
K.   pneumoniae86 have been documented. However, until 
further data are available, tigecyclines routine use against 
these organisms cannot be recommended.
Safety and tolerability of tigecycline
Overall, tigecycline was well tolerated in phase III clinical 
studies for the treatment of CABP and was comparable to Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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those studies performed with tigecycline in the treatment of 
cSSSIs and cIAIs. The most common adverse effect reported 
was nausea (20.8% in community-acquired pneumonia 
(CABP) studies; 34.5% in cSSSIs studies; 24.4% in cIAIs 
studies) and vomiting (13.2% in CABP studies; 19.6% in 
cSSSIs studies; 19.2% in cIAIs studies).12–17,87 Using the 
National Cancer Institute Common Toxicity Criteria, the 
nausea and vomiting was characterized as mild to moder-
ate in severity in most patients in the CABP studies, and 
only led to discontinue therapy in 14 patients.17 Factors that 
have been shown to be associated with a higher incidence 
of nausea and vomiting secondary to tigecycline therapy 
include female gender, ,65 years of age, and non-European 
descent.11   Furthermore, altering the infusion rate and the 
use of antiemetics have not been beneficial in prevention of 
such reactions.11,54 Administration with food may improve 
tolerability.11
Pooled data from the CABP studies utilizing the mITT 
population (n = 846) reported more drug-related adverse 
events with tigecycline compared to the levofloxacin 
(47.9% vs 37.4%, respectively (P , 0.01)).15–17 The most 
common adverse effects noted in the studies were nau-
sea (20.8% vs 6.6%) and vomiting (13.2% vs 3.3%) in 
  tigecycline- and levofloxacin-treated patients, respectively 
(P , 0.001).17 Levofloxacin had a higher incidence of alanine 
aminotransferase (6.4% versus 2.6%) and aspartate amino 
transferase (5.9% vs 2.1%) elevations relative to tigecycline, 
respectively (P , 0.01).17 Other adverse events such as 
diarrhea, phlebitis, and headache were statistically similar 
among treatment groups.17 Serious adverse events resulting 
in extended hospitalizations, readmission to the hospital or 
life-threatening effects (9.9% vs 10.9%), drug discontinua-
tion secondary to adverse effects (6.1% vs 8.1%), and the 
incidence of death not related to study drug (2.8% vs 2.6%) 
were comparable between tigecycline and levofloxacin 
groups, respectively.17 Only one case of Clostridium difficile 
infection was reported in the tigecycline arm.17 Other more 
commonly reported adverse effects with tigecycline include 
diarrhea (7.5%), phlebitis (4%), and headache (3.5%).17 
Other additional adverse effects reported with tigecycline 
from postmarketing surveillance since its food and drug 
administration (FDA) approval include anaphylaxis and 
anaphylactoid reactions, acute pancreatitis, elevated liver 
function tests, hyperbilirubinemia, jaundice, and hepatic 
cholestasis.11,88–90
Recent, pooled analysis from 13 phase III and IV clinical 
studies evaluating the use of tigecycline (n = 3788) versus 
other antibiotics (n = 3646) in the treatment of various serious 
infections have demonstrated an increased risk with the use 
of tigecycline for all-cause mortality (4% vs 3%, (adjusted 
risk difference based on a random effects model stratified by 
trial weight 0.6; 95% CI: 0.1, 1.2)).11,91 The increase in mor-
tality was particularly noted for cSSSIs, cIAIs, diabetic foot 
  infections, and in HAP patients with VAP. Although mortality 
rates in these infections individually did not reach statistical 
significance, the incidence was higher for each infection in 
the tigecycline group and when pooled, there was a statisti-
cally significant difference. In patients with CABP, all-cause 
mortality rates of 2.8% in the tigecycline arm (12/424) com-
pared to 2.6% in the alternate treatment arm (11/422) (risk 
difference 0.3 (95% CI: −2.0, 2.4)). In patients with HAP, 
the incidence of all-cause death was 14.1% (66/467) in the 
tigecycline arm versus 12.2% (57/467) in the comparator 
arm (risk difference 0.60.2 (95% CI: −2.4, 6.3)). Mortal-
ity rates in patients with VAP were 19.1% (25/131) versus 
12.3% (15/122) for tigecycline and the comparator arm, 
respectively (risk difference: 6.8; 95% CI: −2.1, 15.7). It has 
been speculated that this increased incidence of mortality in 
the tigecycline arms may have been due to progression of 
infection while on therapy, possibly secondary to the static 
nature of the drug; however, there is limited data currently 
to support that bactericidal drugs are more efficacious than 
bacteriostatic drugs.92
Tigecycline should be avoided in pregnant women 
(pregnancy category D) and in growing children due to an 
accumulation of the drug in bones; thus resulting a delay 
in ossification.11,58,63 Additionally, similar to tetracyclines, 
teeth discoloration during tooth development may occur from 
the use of tigecycline and should, therefore, be avoided in 
children below the age of eight.11
Drug interactions
Tigecycline is neither metabolized nor does it cause altera-
tions to the cytochrome P450 system; thus, drug interac-
tions mediated through this system have not been identified 
and significant drug interactions have not been reported.11 
Although studies in healthy volunteers administered tige-
cycline concomitantly with digoxin failed to detect any 
significant drug interactions, the clearance of the R and 
S enantiomers of warfarin were decreased.11,93,94 Therefore, 
the international normalized ratio and signs and symptoms 
of bleeding should be monitored if patients are receiving 
tigecycline concurrently with warfarin.11,94 Additionally, 
similar to other antibiotics, concurrent administration of 
tigecycline with oral contraceptives may reduce the efficacy 
of these agents.11Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Health care resource utilization 
perspective
In an analysis of health care resource utilization data from 
CABP patients receiving either tigecycline (n = 393) or levo-
floxacin (n = 403), no difference was reported between the 
groups in terms of mean length of hospital stay (9.8 days for 
each group; P = 0.883) or mean duration of study antibiotic 
(9.8 days tigecycline vs 10 days levofloxacin group; P = 0.511). 
Additionally, there was no difference between groups in the 
rate of rehospitalization, admission to the ICU or emergency 
room, use of home health, or admission to the nursing home. 
The need for concurrent antibiotics during or after discharge 
was lower in the tigecycline group compared to the levofloxacin 
group (5.6% vs 11.7% (P = 0.002), respectively).17
Patient-focused perspective/
conclusion
Initial empiric treatment of CABP in hospitalized patients 
often involves the use of broad-spectrum antibiotics, and 
combination therapy is frequently indicated (especially in 
treatment options excluding respiratory fluoroquinolones). 
With its broad spectrum of activity against most common 
respiratory pathogens causing CABP, tigecycline offers an 
antibiotic option that can be used as monotherapy. Patients 
with a history of β-lactam or quinolone allergy, or patients 
with organisms resistant to alternate therapies may also 
benefit from the use of tigecycyline. Although patients fail-
ing therapy with alternative agents might be considered for 
therapy with tigecycline, data in this population is sparse.
With the possible exception of gastrointestinal intoler-
ance, tigecycline was reasonably well tolerated in this patient 
population.17 Tigecycline is only available in an IV formula-
tion. Therefore, its use for CABP would likely be limited 
largely to patients requiring hospitalization. Alternate therapy 
would be required for conversion to oral therapy. Data for the 
treatment of Staphylococcus aureus and MRSA pneumonias 
are somewhat limited. Recent concerns have emerged regard-
ing tigecycline use in patients with severe forms of CABP 
related to data obtained in patients with other forms of severe 
infection, including HAP.
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